文献速递病毒性肝炎医院感染防控

HBeAg 识别乙肝母婴传播高危孕妇的准确性:系统综述与荟萃分析

Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis.
PubMed 文献 · Lancet Infect Dis · 2020-08-14

该研究由世界卫生组织委托,系统检索 2000 年至 2019 年文献,纳入 67 篇文章(66 项研究),评估孕妇 HBeAg 检测识别 HBV DNA 高水平及预测母婴传播的准确性。结果显示,HBV DNA 阈值 5·30 log10 IU/mL 是免疫预防失败的关键界值,HBeAg 识别该阈值的合并敏感度为 88·2%、特异度为 92·6%,预测母婴传播的敏感度为 99·5%、特异度为 62·2%。在无法检测 HBV DNA 的地区,HBeAg 可作为评估抗病毒预防资格的替代方法。

要点

  • 孕妇 HBV DNA≥5·30 log10 IU/mL 是免疫预防失败的关键阈值。
  • HBeAg 识别该阈值的敏感度 88·2%、特异度 92·6%。
  • HBeAg 预测母婴传播敏感度 99·5%,可用于筛查高危孕妇。

核心结论

  • 母亲 HBV DNA≥5·30 log10 IU/mL 是尽管婴儿接受免疫预防仍发生母婴传播的最佳阈值。
  • HBeAg 能准确识别 HBV DNA 高于该阈值的孕妇,预测免疫预防失败有高敏感度。
  • 在无法检测 HBV DNA 的地区,HBeAg 可作为评估抗病毒预防资格的替代方法。

研究设计与样本

  • 世界卫生组织委托的系统综述与荟萃分析,检索 PubMed、EMBASE、Scopus、CENTRAL、CNKI、Wanfang 数据库。
  • 检索 2000 年 1 月 1 日至 2019 年 4 月 3 日发表的研究,纳入无同期抗病毒治疗的慢性 HBV 感染孕妇。
  • 共 9007 篇文章中 67 篇文章(66 项研究)符合纳入标准。
  • 采用 DerSimonian-Laird 双变量随机效应模型合并敏感度与特异度,PROSPERO 注册号 CRD42019138227。

主要发现

  • 母亲 HBV DNA 低于 5·30 log10 IU/mL(200 000 IU/mL)时,婴儿免疫预防后母婴传播风险可忽略(0·04%,95% CI 0·00-0·25),高于该阈值后风险上升。
  • HBeAg 检测识别孕妇 HBV DNA≥5·30 log10 IU/mL 的合并敏感度为 88·2%(83·9-91·5),合并特异度为 92·6%(90·0-94·5)。
  • HBeAg 检测预测尽管婴儿接受免疫预防仍发生 HBV 母婴传播的合并敏感度为 99·5%(95% CI 91·7-100),合并特异度为 62·2%(55·2-68·7)。

关键数值与推荐

  • 母婴传播风险可忽略的母体 HBV DNA 阈值为 5·30 log10 IU/mL(200 000 IU/mL)。
  • HBeAg 识别 HBV DNA≥5·30 log10 IU/mL 的敏感度 88·2%(83·9-91·5)、特异度 92·6%(90·0-94·5)。
  • HBeAg 预测免疫预防失败所致母婴传播的敏感度 99·5%(95% CI 91·7-100)、特异度 62·2%(55·2-68·7)。

临床怎么用

  • 在 HBV DNA 检测不可及的资源匮乏地区,可用 HBeAg 替代评估孕妇是否需要围产期抗病毒预防。
  • HBeAg 阳性对预测免疫预防失败敏感度高,有助于识别高危孕妇并加强随访。
  • HBeAg 特异度有限,阳性孕妇仍应结合临床评估以决定抗病毒预防策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prevention of mother-to-child transmission (MTCT) of hepatitis B virus (HBV) involves neonatal immunoprophylaxis, with a birth dose of hepatitis B vaccine and immune globulin, and provision of peripartum antiviral prophylaxis in highly viraemic women. However, access to assays to quantify HBV DNA levels remains inadequate in resource-poor settings. This study was commissioned by WHO and aimed to identify the HBV DNA threshold for MTCT, to assess the sensitivity and specificity of hepatitis B e antigen (HBeAg) testing to identify pregnant women with HBV DNA levels above this threshold, and to predict MTCT of HBV infection on the basis of HBeAg testing. METHODS: For this systematic review and meta-analysis, we searched the PubMed, EMBASE, Scopus, CENTRAL, CNKI, and Wanfang databases for studies of pregnant women with chronic HBV infection without concurrent antiviral therapy, published between Jan 1, 2000, and April 3, 2019. Studies were eligible for inclusion if MTCT in mother-child pairs could be stratified by different levels of maternal HBV DNA during pregnancy, if maternal HBeAg status could be stratified by HBV DNA level, and if the MTCT status of infants could be stratified by maternal HBeAg status during pregnancy. Studies that selected pregnant women on the basis of HBeAg serostatus or HBV DNA levels were excluded. Aggregate data were extracted from eligible studies by use of a pre-piloted form; study authors were contacted to clarify any uncertainties about potential duplication or if crucial information was missing. To pool sensitivities and specificities of maternal HBeAg to identify highly viraemic women and to predict MTCT events, we used the DerSimonian-Laird bivariate random effects model. This study is registered with PROSPERO, CRD42019138227. FINDINGS: Of 9007 articles identified, 67 articles (comprising 66 studies) met the inclusion criteria. The risk of MTCT despite infant immunoprophylaxis was negligible (0·04%, 95% CI 0·00-0·25) below a maternal HBV DNA level of 5·30 log10 IU/mL (200 000 IU/mL) and increased above this threshold. The pooled sensitivity of HBeAg testing to identify HBV DNA levels of 5·30 log10 IU/mL or greater in pregnant women was 88·2% (83·9-91·5) and pooled specificity was 92·6% (90·0-94·5). The pooled sensitivity of HBeAg testing in predicting MTCT of HBV infection despite infant immunoprophylaxis was 99·5% (95% CI 91·7-100) and pooled specificity was 62·2% (55·2-68·7). INTERPRETATION: Maternal HBV DNA of 5·30 log10 IU/mL or greater appears to be the optimal threshold for MTCT of HBV infection despite infant immunoprophylaxis. HBeAg is accurate to identify women with HBV DNA levels above this threshold and has high sensitivity to predict cases of immunoprophylaxis failure. In areas where HBV DNA assays are unavailable, HBeAg can be used as an alternative to assess eligibility for antiviral prophylaxis. FUNDING: World Health Organization.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Boucheron P, Lu Y, Yoshida K, et al. Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis. Lancet Infect Dis. 2020. PMID: 32805201. doi:10.1016/S1473-3099(20)30593-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。